Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 5/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | NCF1 | P14598 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 3/20 | 0.31 |
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.30 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11613094 | 0.98 | TAAR1 (0.35) | TAAR1CHRNB2CHRNA4SLC6A2SLC6A4 | |
| SCHEMBL11610028 | 0.90 | TAAR1 (0.39) | TAAR1CHRNB2CHRNA4HTR2CEPHX2 | |
| Hydrochloric Acid SCHEMBL11608370 | 0.88 | TAAR1 (0.38) | TAAR1CHRNB2CHRNA4HTR2CEPHX2 | |
| SCHEMBL10864329 | 0.82 | TAAR1 (0.35) | TAAR1CHRNB2CHRNA4HTR2CEPHX2 | |
| Romifidine SCHEMBL5898394 | 0.76 | PARP10 (0.31) | — | |
| Romifidine SCHEMBL9623631 | 0.75 | PARP10 (0.30) | — | |
| SCHEMBL10878909 | 0.71 | — | — | |
| SCHEMBL14256871 | 0.71 | PTGS2 (0.38) | TRPA1HSD11B1SMN1; SMN2 | |
| SCHEMBL10880614 | 0.69 | GLA (0.37) | — | |
| SCHEMBL11088921 | 0.67 | LRRK2 (0.41) | HSD11B1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4125620-A | HYPOTENSIVE | BOEHRINGER INGELHEIM GMBH (DE) | 1978-11-14 | — | — | US | claimed |
| EP-0821585-B1 | USE OF ALPHA 1L-AGONISTS IN THE TREATMENT OF URINARY INCONTINENCE | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-01-10 | — | — | EP | disclosed |
| US-7019021-B2 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-03-28 | — | — | US | disclosed |
| US-6858594-B2 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG. (DE) | 2005-02-22 | — | — | US | disclosed |
| US-20040198796-A1 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-10-07 | — | — | US | disclosed |
| US-20030114425-A1 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-06-19 | — | — | US | disclosed |
| EP-1285653-A1 | Use of alpha-1L agonists in the treatment of incontinence | Boehringer Ingelheim Pharma KG (DE) | 2003-02-26 | — | — | EP | disclosed |
| US-6268389-B1 | Treatment of urinary incontinence by administration of α1L-adrenoceptor agonists | BOEHRINGER INGELHEIM KG (DE) | 2001-07-31 | — | — | US | disclosed |
| EP-0821585-A1 | USE OF $g(a) 1L? AGONISTS IN THE TREATMENT OF INCONTINENCE | BOEHRINGER INGELHEIM KG (DE) | 1998-02-04 | — | — | EP | disclosed |
| WO-1996032939-A1 | USE OF α1L AGONISTS IN THE TREATMENT OF INCONTINENCE | BOEHRINGER INGELHEIM KG (DE) | 1996-10-24 | — | — | WO | disclosed |
| EP-0202461-A1 | Substituted derivatives of 2-(N-alkenyl-N-phenyl-amino) imidazoline, their acid addition salts, medicaments containing them and process for their preparation | BOEHRINGER INGELHEIM KG (DE) | 1986-11-26 | — | — | EP | disclosed |
| US-4478844-A | Bradycardiac or analgesic 2-(N-(thienyl-2-methyl)-N-(2-fluoro-6-methyl-phenyl)-amino)-2-imidazoline and salts thereof | BOEHRINGER INGELHEIM KG (DE) | 1984-10-23 | — | — | US | disclosed |
| EP-0031429-A1 | 2-(N-(2-Fluoro-6-bromophenyl)-N-(thiemyl-2-methyl)-amino)-2-imidazoline, its addition salts, pharmaceutical compositions containing them and processes for their preparation | C.H. BOEHRINGER SOHN (DE) | 1981-07-08 | — | — | EP | disclosed |
| US-4100292-A | ANALGESIC | BOEHRINGER INGELHEIM GMBH (DE) | 1978-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114425-A1 | Compounds and methods for treating urinary incontinence | PDE3A, PDE3B, PDE2A | TAAR1 232/4885CHRNB2 153/4885CHRNA4 178/4885 |
| US-20040198796-A1 | Compounds and methods for treating urinary incontinence | REN, ARG1, RXFP1 | TAAR1 1280/4885CHRNB2 1637/4885CHRNA4 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.